• Earlier this week, NeoGenomics, Inc. announced that its oncology testing portfolio is now integrated into Epic Aura, allowing oncologists and health systems across the US to order its solid tumor and hematologic malignancy tests and view results directly within the Epic electronic health record.
• This “build once, deploy broadly” digital infrastructure could materially ease adoption barriers for hospitals, helping NeoGenomics scale future offerings such as liquid biopsy and molecular residual disease testing across community and large health system settings.
• We’ll now examine how this expanded Epic Aura integration, which may boost test adoption per site, affects NeoGenomics’ investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

NeoGenomics Investment Narrative Recap

To own NeoGenomics, you need to believe that its expanding oncology testing menu and digital infrastructure can eventually support more predictable growth despite current losses and competitive pressure. The Epic Aura integration may reinforce the near term catalyst of scaling PanTracer and RaDaR by making ordering and result viewing easier inside hospital workflows, but it does not eliminate key risks around high fixed costs, intense NGS competition, and uncertainty in product ramp and reimbursement.

The recent Medicare coverage decision for the PanTracer LBx liquid biopsy test is especially relevant here, as it pairs clinical access and reimbursement with the new Epic Aura connectivity. Together, these developments could support broader use of liquid biopsy and MRD testing once physicians can both get paid for the test and order it within their existing EHR systems, which is central to the current thesis that NeoGenomics can expand adoption of its newer, higher value assays.

Yet investors should be aware that the biggest concern may be...

NeoGenomics' narrative projects $957.8 million revenue and $49.0 million earnings by 2029. This requires 9.6% yearly revenue growth and a $157.0 million earnings increase from -$108.0 million today.

Uncover how NeoGenomics' forecasts yield a $14.19 fair value, a 71% upside to its current price.

Exploring Other Perspectives

By contrast, the most bearish analysts saw revenue growing about 9.9% annually to roughly US$966,000,000 by 2029, while still questioning profitability, so this new Epic Aura integration could eventually challenge or reinforce that more pessimistic view depending on how much it actually lifts test volumes and accelerates adoption.

Explore 2 other fair value estimates on NeoGenomics - why the stock might be worth just $14.19!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your NeoGenomics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free NeoGenomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NeoGenomics' overall financial health at a glance.

Curious About Other Options?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.